These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33523385)

  • 1. Molecular Characteristics of Thalamic Gliomas in Adults.
    Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
    J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of diffuse intrinsic brainstem gliomas in adults.
    Reyes-Botero G; Giry M; Mokhtari K; Labussière M; Idbaih A; Delattre JY; Laigle-Donadey F; Sanson M
    J Neurooncol; 2014 Jan; 116(2):405-11. PubMed ID: 24242757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK
    BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor location and patient age predict biological signatures of high-grade gliomas.
    Altieri R; Zenga F; Ducati A; Melcarne A; Cofano F; Mammi M; Di Perna G; Savastano R; Garbossa D
    Neurosurg Rev; 2018 Apr; 41(2):599-604. PubMed ID: 28856492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
    Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
    Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
    Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
    Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.
    Rao S; Kanuri NN; Nimbalkar V; Arivazhagan A; Santosh V
    Neuropathology; 2019 Apr; 39(2):78-84. PubMed ID: 30937985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
    Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
    Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
    Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
    Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
    J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
    Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
    Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.